MARKET

CYTK

CYTK

Cytokinetics Inc
NASDAQ
56.18
+1.04
+1.89%
After Hours: 56.98 +0.8 +1.42% 19:56 11/10 EST
OPEN
54.67
PREV CLOSE
55.14
HIGH
57.21
LOW
54.12
VOLUME
2.36M
TURNOVER
--
52 WEEK HIGH
88.31
52 WEEK LOW
53.55
MARKET CAP
7.83B
P/E (TTM)
-9.3049
1D
5D
1M
3M
1Y
5Y
1D
Cytokinetics announces additional aficamten data in hypertrophic cardiomyopathy
TipRanks · 1d ago
Cytokinetics’ Aficamten Data Strengthen HCM Outlook, Supporting Buy Rating and Unchanged $140 Price Target
TipRanks · 1d ago
Cytokinetics Presents New Aficamten Data From ACACIA-HCM And FOREST-HCM At HCMS Scientific Sessions 2026
Benzinga · 1d ago
Cytokinetics, Incorporated (NASDAQ:CYTK) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
Simply Wall St · 1d ago
Weekly Report: what happened at CYTK last week (1102-1106)?
Weekly Report · 1d ago
What Cytokinetics (CYTK)'s MYQORZO Launch Means For Shareholders
Simply Wall St · 4d ago
Truist Financial Sticks to Its Buy Rating for Cytokinetics (CYTK)
TipRanks · 4d ago
Cytokinetics (CYTK) Stock Looks Hard To Judge On Book Value
Simply Wall St · 5d ago
More
About CYTK
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.

Webull offers Cytokinetics, Inc. stock information, including NASDAQ: CYTK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYTK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CYTK stock methods without spending real money on the virtual paper trading platform.